Dr. Bernard A. Fox, internationally known expert in immunotherapy will meet with other cancer experts here Saturday to discuss recent advances in treatments that hold promise for improved treatments and increased survival for patients with cancer.
UbiVac, www.ubivac.com, announced the results of their randomized phase II adjuvant clinical trial in patients with definitively-treated Stage III non-small cell lung cancer (NSCLC).
UbiVac CEO Dr. Bernard A. Fox will address London meeting on developing anti-cancer immunotherapeutic drugs
Immunotherapy Research Scientist Dr. Bernard Fox Receives International Award for Advancing Innovative Treatments to Cure Cancer
Washington DC—A Portland, Ore. specialist in the area of immunotherapy has been awarded the prestigious Visionary/Legacy Award by the Society for Immunotherapy of Cancer (SITC) at its 30th Anniversary Award Ceremony here. Dr.
UbiVac CEO Bernard A. Fox to Head Discussion on Immunotherapy and Translational Oncology at Providence Cancer Center
Portland, Ore.—Internationally known immunotherapy expert Bernard A. Fox, PhD, chief executive officer of UbiVac, www.ubivac.com , will be heading a panel of specialists speaking on October 20, 6:00 to 8:00 pm, at the Earle A. Chiles
UbiVac Announces Collaboration with Johnson & Johnson Innovation to Develop and Test, in Preclinical Studies, a Vaccine to Intercept Oral Cancer
PORTLAND, OR., Sept. 29, 2015 /PRNewswire/ — UbiVac, www.ubivac.com, a privately held clinical stage Immuno-Oncology
UbiVac CEO Presents at the China Center for Food and Drug International Exchange’s China Cancer Immunotherapy Workshop
Beijing, China—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, has announced that its co-founder and CEO, Bernard A. Fox, PhD, has been
Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in Chicago
Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the 2015 Sachs
Portland, Ore.—UbiVac, www.ubivac.com, a spinout biotechnology company of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Portland Medical Center, has announced two internationally renowned research scientists to
Portland-based Immunotherapy Research Scientist Dr. Bernard Fox To Address Medical Conference in Tokyo
Portland, Ore—Bernard A. Fox, PhD, president and chief executive officer of Ubivac, www.ubivac.com, a spinout biotechnology company of the Robert W. Franz Cancer and Research Center within the Earle A. Chiles Research Institute at Providence
Washington DC, — UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced additional details on UbiVac’s first-in-class autophagosome DRibble vaccine, DPV-001, in three presentations at the 28th Annual meeting of the Society
SYDNEY, Nov. 5, 2013 /PRNewswire/ — UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of
Beating 15 other startups, Oregon company CEOs judge UbiVac as best new bioscience company at the Oregon Bioscience Association’s annual conference, as the growing firm seeks to initiate its second clinical trial as early as
Autophagosome-enriched cancer vaccine strategy provides a novel non-genetic method to engineer leukocytes to express molecules that may augment cancer immunotherapy. (P4252)
Christopher Paustian,1Traci Hilton,2Rieneke Van De Ven,1Daniel Haley,3Chris Twitty,1Hong-Ming Hu,4Bernard Fox,1 and Sandra Aung2
1Molecular and Tumor Immunology, PPMC EACRI, Portland, OR 2UbiVac, Portland, OR 3Immunological Monitoring Lab, PPMC EACRI, Portland, OR 4Cancer Immunobiology, Earle A. Chiles